Johnson & Johnson Sees Bullish Options Surge as $2.3M in Call Premiums Target July Upside
By TrendSpider Editor
Johnson & Johnson attracted notable bullish options activity on Friday, with two unusual call contracts totaling $2,344,500 in premium pointing to upside conviction heading into mid-July. The larger of the two bets targets a breakout to $240, a level that would represent a meaningful extension from
Johnson & Johnson Sees Bullish Options Surge as $2.3M in Call Premiums Target July Upside
Johnson & Johnson attracted notable bullish options activity on Friday, with two unusual call contracts totaling $2,344,500 in premium pointing to upside conviction heading into mid-July. The larger of the two bets targets a breakout to $240, a level that would represent a meaningful extension from the current price of $231.50. With JNJ trading well above its 52-week low of $149.04 but still below its 52-week high of $251.705, the stock sits in a constructive position where options traders appear to be positioning for a continued climb.
Key Drivers of the JNJ Stock Move
- Main Catalyst: Two unusual call contracts were flagged today, both expiring July 17, 2026. The dominant trade was a $240 strike call with 5,000 contracts and $1,950,000 in premium, followed by a $230 strike call with 500 contracts and $394,500 in premium. Combined, the two contracts represent $2,344,500 in total premium.
- Bull Case: The $240 strike call carries an open interest percentage of 51%, signaling strong conviction and significant positioning relative to existing open interest. JNJ is already up 1.37% on the session to $231.50, and with the 52-week high sitting at $251.705, there is meaningful room to run if momentum continues. The $230 strike call is essentially at the money, suggesting traders are also hedging for near-term upside from current levels.
- Bear Case: Both contracts are out-of-the-money or at-the-money calls with a tight expiration window of just over six weeks, meaning time decay will work against these positions quickly if JNJ fails to move higher. The $240 strike requires roughly a 3.7% move from today's close to reach breakeven before the options lose significant value. A reversal from the current rally or broader market weakness could render both contracts worthless.
The forward setup for JNJ looks constructive from a technical standpoint. The stock has recovered substantially from its 52-week low of $149.04 and is trading in the upper half of its annual range, within striking distance of the $251.705 high. The concentration of call activity at the $240 level through July 17 suggests that at least some institutional players expect a catalyst or continued price appreciation over the next six weeks. Whether that catalyst is an upcoming earnings report, pipeline news, or broader sector rotation into healthcare remains to be seen, but the options flow clearly reflects a bullish near-term bias.
JNJ Unusual Options Activity
- Contract 1: Call | Strike: $240 | Expiry: July 17, 2026 | Volume: 5,000 | Open Interest Percentage: 51% | Out of the Money | Premium: $1,950,000
- Contract 2: Call | Strike: $230 | Expiry: July 17, 2026 | Volume: 500 | Open Interest Percentage: 8% | At the Money | Premium: $394,500
Both contracts are calls expiring on the same date, with zero put activity flagged. The total unusual premium across the two contracts is $2,344,500, and the directional skew is entirely to the upside. The 5,000-contract size on the $240 strike is the standout trade, representing the overwhelming majority of total premium and suggesting a single large participant is behind the positioning.
JNJ Seasonality
June and July have historically been a mixed-to-positive period for healthcare stocks, with mid-summer often seeing increased activity around medical conference season and quarterly earnings cycles. With both contracts expiring July 17, the positioning aligns with a timeframe that could capture any second-quarter earnings catalyst for JNJ.
JNJ Relative Performance
JNJ gained 1.37% on Friday to close at $231.50, outperforming what has been a broadly range-bound environment for large-cap healthcare names. Trading near the upper half of its 52-week range of $149.04 to $251.705, JNJ is demonstrating relative strength, and today's options flow suggests sophisticated market participants expect that outperformance to continue into next month.